The following full text is a publisher's version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/29204

Please be advised that this information was generated on 2019-02-20 and may be subject to change.
Differential Effects of Midazolam and Zolpidem on Sleep-Wake States and Epileptic Activity in WAG/Rij Rats


*Synthélabo Recherche (L.E.R.S.), 31, avenue Paul Vaillant Couturier, F-92220 Bagneux, France
†NICI, Department of Psychology, University of Nijmegen, Nijmegen, The Netherlands

Received 1 September 1994; Revised 14 January 1995; Accepted 17 January 1995

DEPOORTERE, H., D. FRANCON, E. L. J. M. VAN LUIJTELAAR, W. H. I. M. DRINKENBURG AND A. M. L. COENEN. Differential effects of midazolam and zolpidem on sleep-wake states and epileptic activity in WAG/Rij rats. PHARMACOL BIOCHEM BEHAV 51(4) 571-576, 1995. — Hypnotic drugs are known to possess antiepileptic activity. Therefore, the effects of the benzodiazepine hypnotic midazolam (10 mg/kg) and the novel imidazopyridine hypnotic zolpidem (10 mg/kg) on sleep-wake states and on the number of spike-wave discharges were evaluated in WAG/Rij rats. Rats of this strain are considered to be a model for generalized absence epilepsy. Animals were implanted with chronic monopolar EEG electrodes and, after recovery from surgery, the EEG was recorded for 6 h during the dark period on 3 consecutive days. Sleep recordings were analyzed using Hjorth's parameters and number and duration of spike-wave discharges were visually determined. It was found that both drugs facilitated nonREM sleep at the cost of wakefulness. Both hypnotics also reduced the number and duration of spike-wave discharges. The initial decrease after midazolam, however, was followed by a rebound reflecting a poorer quality of vigilance expressed as an increase in spike-wave discharges. The strong antiabsence activity of zolpidem mimics that of midazolam and is well correlated with their equipotent hypnotic action and anticonvulsant effect in the isoniazid test.

Sleep-wake states  Spike-wave discharges  Absence epilepsy  Midazolam  Zolpidem  Hypnotics
WAG/Rij strain  Rats  Rebound effects

FOR THE last 2 decades benzodiazepines have been the anxiolytics and hypnotics of first choice due to their efficacy, their relatively mild side effects, and their safety. A standing problem is that they also induce daytime drowsiness, which is often accompanied by muscular relaxation (6). Moreover, it has become increasingly clear that benzodiazepines affect cognitive functioning and psychomotor performance (16,20,25). Next to all these actions, benzodiazepines show broad spectrum antiepileptic properties: they reliably reduce various types of convulsions and counteract spike-wave discharges.

Until recently, it was generally assumed that these different effects of benzodiazepines are indissolubly linked. Nowadays, research efforts are aimed at separating the different actions of the benzodiazepines, and new drugs are currently being developed that do not possess all the effects of the benzodiazepines. Investigations of partial agonists at the benzodiazepine (ω) receptors suggest that it is, indeed, possible to separate these effects. Concrete examples were presented by Coenen and van Luijtelaar (3), who demonstrated that the hypnotic and antiepileptic action of ZK 91296 were discriminable. Stephens et al. (24) and Coenen et al. (5) also showed that the anxiolytic and hypnotic actions of abecarnil were distinguishable.

The novel hypnotic, zolpidem, an imidazopyridine derivative, shares many of the pharmacological actions characteristic of benzodiazepines. There are, however, differences such as the weaker myorelaxant effects of zolpidem (1,10). Depoortere et al. (10) investigated the anticonvulsant profile of zolpidem in pentylenetetrazol-induced convulsions and in the electroshock model. They demonstrated a considerable weaker anticonvulsant activity for zolpidem than for the benzodiazepines midazolam, triazolam, and flunitrazepam in...
these models. However both categories of drugs, ligands of the GABA-benzodiazepine receptor complex, have equipotent hypnotic activity (11), as well as anticonvulsant effects in the isoniazid convulsant model (30). Based on the latter findings, it is likely that zolpidem, like the benzodiazepines, inhibits spike-wave discharges.

The purpose of the present study was to evaluate the effects on sleep-wake states and on the amount of epileptic activity of the classical benzodiazepine hypnotic midazolam and the nonbenzodiazepine hypnotic zolpidem. This was done in WAG/Rij rats, which show spontaneously occurring spike-wave discharges in the EEG and are considered as an adequate model for human absence epilepsy (4,27).

**METHOD**

Experiments were performed on 10 male WAG/Rij rats, weighing between 320 and 400 g. They were maintained under identical environmental conditions, under a 12 L : 12 D cycle and a constant temperature of 21°C. Rats were anesthetized with an intraperitoneal injection of 50 mg/kg sodium pentobarbital and implanted with three small electrode screws on each hemisphere. The first electrode was screwed into the skull above the sensorimotor cortex (1.5 mm lateral to the median suture and 1.5 mm behind the fronto-parietal suture), the second one into the skull above the visual cortex (1.5 mm lateral to the median suture and 1.5 mm in front of the parieto-occipital suture), and the third one above the cerebellum. All electrodes were attached to a seven-lead Winchester connector fixed with dental cement to the cranium. Three weeks of postoperative recovery were allowed. During this period, half of the rats were habituated to a reversed light : dark cycle, whereas the other half kept the regular cycle with lights on between 0700 and 1900 h. There was no difference between the two groups of five rats: they had the same ages and weights (360 ± 20 g). Four days before the experiment, the animals were placed in Plexiglas cylinders with free access to food and water (habituation period to experimental conditions). Each rat was injected twice at intervals of at least 3 weeks and recorded from during the light period after treatment with vehicle (control midazolam) were conducted during 3 consecutive days in five rats: they had the same ages and weights (360 ± 20 g). They were maintained under identical environmental conditions, under a 12 L : 12 D cycle to evaluate hypnotic effects and antilapseence effect on spike-wave discharges (9,28,29). Spike-wave discharges were counted based on criteria published elsewhere, whereby the number and total duration of the spike-wave discharges per hour were determined (27). Within-group comparisons were made with Student's t-test for paired observations.

**RESULTS**

Sleep-wakefulness characteristics for the baseline light and dark period are presented in Table 1. This table shows that the rats predominantly slept during the light period (74% of total time) and that the percentages of non-REM sleep and REM sleep, the number of REM periods, and the mean length of periods of REM sleep were greater in the light than in the dark period. The rats had more spike-wave discharges during the dark period (mean and standard error: 197 ± 21) than during the light period (85 ± 8).

Zolpidem reduced wakefulness and increased non-REM sleep during the first 2 h following administration. No significant effects were seen on REM sleep. The data are shown in Fig. 1a. One day later, non-REM sleep was reduced and wakefulness was increased for the first hour of recording. Zolpidem decreased the number and total duration of spike-wave discharges (Fig. 2a). These effects were present during the first 3 h after administration. The number and duration of the spike-wave discharges on the postdrug day did not differ from predrug values, except that the duration was still reduced during the first hour on the postdrug day.

Midazolam increased non-REM sleep and reduced wakefulness. The results are shown in Fig. 1b. Midazolam reduced the number and duration of spike-wave discharges during the first 3 h following drug administration (Fig. 2b). This initial decrease was followed by a significant increase in number and total duration at the fifth hour of the experimental day. The total duration of the spike-wave discharges was still enhanced

**TABLE 1**

**SLEEP-WAKEFULNESS PARAMETERS OF WAG/Rij RATS RECORDED DURING THE LIGHT AND THE DARK PERIOD (MEAN OF TWO EXPERIMENTS ON FIVE RATS)**

<table>
<thead>
<tr>
<th>Recordings During</th>
<th>W%</th>
<th>non-REM%</th>
<th>REM%</th>
<th>nREM</th>
<th>xREM s</th>
<th>nSWD</th>
<th>dSWD s</th>
</tr>
</thead>
<tbody>
<tr>
<td>Light</td>
<td>24.2 ± 1.5</td>
<td>65.4 ± 1.1</td>
<td>10.4 ± 1.3</td>
<td>19 ± 1</td>
<td>116 ± 7</td>
<td>85 ± 8</td>
<td>440 ± 82</td>
</tr>
<tr>
<td>Dark</td>
<td>59.2 ± 2.5</td>
<td>38.6 ± 2.5</td>
<td>2.2 ± 0.8</td>
<td>7 ± 2</td>
<td>89 ± 3</td>
<td>197 ± 21</td>
<td>1534 ± 159</td>
</tr>
</tbody>
</table>

The results (± SEM) are expressed as percentages for wakefulness (W), non-REM sleep, REM sleep, number of REM periods (nREM), mean duration of REM periods in s (xREM), number of spike-wave discharges (nSWD), and total duration of spike-wave discharges in seconds (dSWD) in a 6-h recording period during the first control day.
on the sixth hour after administration and during the first hour on the postdrug day; this was followed by a steady decline to predrug levels.

An overview of the main outcomes is presented in Table 2. Both drugs facilitated non-REM sleep at the expense of wakefulness and reduced the number and duration of spike-wave discharges with a similar efficacy. On the second control day, the two drugs differed in that zolpidem decreased non-REM sleep and the number of spike-wave discharges while midazolam increased spike-wave activity.

**DISCUSSION**

The sleep-wakefulness profile of WAG/Rij rats differs from that commonly seen in other laboratory rats. The low percentage REM sleep for the dark period (2%) seems to be smaller than commonly reported (5%) (2,9,18,26). Also, the duration of the REM periods seems to be shorter than found earlier for outbreds in the same laboratory (7). Thus, it seems that WAG/Rij rats spend less time in REM sleep than other rats, and this was directly evaluated by Gandolfo et al. (13) who reported that WAG/Rij rats have less REM sleep periods per hour, with a lower percentage of REM sleep, and that these rats seemed to have difficulties entering into REM sleep.

Despite differences in genotype between outbred and WAG/Rij rats, it seems that both midazolam and zolpidem reliably induce nonREM sleep at the cost of wakefulness (Table 2). The hypnotic effects of zolpidem were earlier described by Depoortere et al. (10,11), and the present results suggest that the hypnotic effects of both drugs are independent of the rat's genotype. However, the two drugs differ in their effects on rebound spike-wave discharges and on sleep 24 h following
FIG. 2. (a) Effects of zolpidem (10 mg/kg PO) on number and total duration of spike-wave discharges in WAG/Rij rats (n = 5). *p ≤ 0.05; **p ≤ 0.01 vs. control values. (b) Effects of midazolam (10 mg/kg PO) on number and total duration of spike-wave discharges in WAG/Rij rats. (n = 5). *p ≤ 0.05; **p ≤ 0.01 vs. control values.
EFFECTS OF MIDAZOLAM AND ZOLPIDEM IN WAG/Rij Rats

## Table 2

<table>
<thead>
<tr>
<th></th>
<th>Zolpidem</th>
<th>Midazolam</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Control</td>
<td>10 mg/kg PO</td>
</tr>
<tr>
<td>W (sec)</td>
<td>12600 ± 501</td>
<td>11591 ± 525</td>
</tr>
<tr>
<td>non-REM (sec)</td>
<td>8491 ± 444</td>
<td>9766 ± 504</td>
</tr>
<tr>
<td>nSWD</td>
<td>208 ± 19</td>
<td>126 ± 20</td>
</tr>
<tr>
<td>dSWD (sec.)</td>
<td>1805 ± 192</td>
<td>1261 ± 285</td>
</tr>
</tbody>
</table>

*p ≤ 0.05 Student's t-test for paired values. For legends, see Table 1.

When administered, zolpidem induced a decrease of non-REM sleep during waking (dark) period, which was not found for midazolam. Zolpidem does not appear to cause rebound insomnia or to have residual sedative effects in the morning in humans (19), although these phenomena are well known with benzodiazepines (14, 17, 21).

The decrease in the number and duration of spike-wave discharges after midazolam was expected considering the well-known antiepileptic action of benzodiazepines (22). However, the reduction in spike-wave discharges seen with zolpidem was as marked as that of midazolam. It is known that the anticonvulsant action of zolpidem in pentylentetrazol-induced seizures or in electroshock convulsions is less than those of the benzodiazepines flunitrazepam and midazolam (10). Thus, zolpidem is 225 and 69 times less potent than flunitrazepam and midazolam, respectively, in pentylenetetrazol-induced convulsions, and 13 and 8 times less potent in electroshock convulsions. On the other hand, zolpidem is more active in convulsive models that involve impairment in GABAergic transmission, e.g., isoniazid-induced convulsions. It possesses the same or an even higher efficacy as compared to flunitrazepam and midazolam, in this model (30). The present data shows that midazolam and zolpidem are equally effective in suppressing spike-wave discharges, and these effects seem to be correlated with their hypnotic and anticonvulsant potency.

The decrease in the number of spike-wave discharges following midazolam was followed by an increase in the number of spike-wave discharges. To our knowledge, rebound effects on spontaneous epileptic activity have not previously been reported. Only following abrupt cessation of chronic benzodiazepine administration was an increase in susceptibility for epileptic seizures reported (23). The rebound effects seen only on spike-wave discharges but not on sleep after midazolam could reflect a poorer quality of vigilance, with an increase of quiet wakefulness-drowsiness periods, because spike-wave discharges preferentially occur during periods with a low level of vigilance (12). In contrast, zolpidem maintains an adequate level of vigilance after its hypnotic effect during the waking (dark) period without rebound of spike-wave discharges.

In all, the present data show comparable hypnotic effects of zolpidem and midazolam in rats with a different genotype than commonly used. They further suggest an equal potency of these drugs to suppress spike-wave discharges in WAG/Rij rats. Finally, the data show a rebound effect on spike-wave activity for midazolam that could reflect a poorer quality of vigilance, but this warrants further investigation.

**Acknowledgements**

The authors gratefully acknowledge A. Clemente and C. Laufrais for their skilled experimental assistance and J. Chartouni for her secretarial help.

**References**